AgingResearch.NewsJoin free

Phase 3Completed

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Sponsor
Eli Lilly and Company (Industry)
Enrollment
1,152 enrolled
Conditions
Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea
Interventions
Retatrutide; Placebo
Ages
adults, older adults
Registry
NCT05929079, CTIS2023-503658-11-00

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Primary outcomes

  • Percent Change from Baseline in Body Weight
  • Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered

Papers citing this trial

In the news

TrialsMedical Xpress (opens Medical Xpress in a new tab)

Lilly’s retatrutide at least halves knee osteoarthritis pain in two-thirds of participants

Two Northwestern-led phase 3 trials enrolled over 1,000 adults with overweight or obesity; 38% on placebo achieved comparable pain relief, while the highest dose produced roughly 25% weight loss.

Also in NEJM (opens NEJM in a new tab), Yonhap News Agency (opens Yonhap News Agency in a new tab)

TrialsSTAT+ (opens STAT in a new tab, subscription)

Eli Lilly says retatrutide lowers blood sugar and weight more than Ozempic in diabetes

The large head-to-head study tested Lilly’s investigational incretin injection against Novo Nordisk’s drug.

Also in Endpoints News (opens Endpoints News in a new tab), BioPharma Dive (opens BioPharma Dive in a new tab), ByDrug (opens ByDrug in a new tab), Diario Médico (opens Diario Médico in a new tab), asiae.co.kr (opens asiae.co.kr in a new tab), oe24 (opens oe24 in a new tab)